Baker Bros. Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Baker Bros. Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,753	Closed	-$3.27M	–	120
2018 Q2	$3.27M	Hold	3,753	–	–	0.02%	89
2018 Q1	$4.72M	Hold	3,753	–	–	0.04%	77
2017 Q4	$5.61M	Hold	3,753	–	–	0.05%	74
2017 Q3	$7.68M	Buy	3,753 +2,353	+168%	+$5.52M	0.06%	61
2017 Q2	$3.67M	Hold	1,400	–	–	0.03%	70
2017 Q1	$4.2M	Hold	1,400	–	–	0.03%	69
2016 Q4	$2.09M	Hold	1,400	–	–	0.02%	92
2016 Q3	$2.47M	Hold	1,400	–	–	0.02%	90
2016 Q2	$2.63M	Hold	1,400	–	–	0.03%	86
2016 Q1	$3.14M	Hold	1,400	–	–	0.03%	86
2015 Q4	$3.37M	Hold	1,400	–	–	0.03%	91
2015 Q3	$3.33M	Buy	+1,400	New	+$3.71M	0.03%	87

Other funds holding NBRV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Baker Bros. Advisors's NBRV Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2018, closing a stake of 3,753 shares — an estimated $3.27M sold.

Baker Bros. Advisors first reported a position in NBRV in Q3 2015 and held it in 12 quarters. The position peaked at $7.68M in Q3 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q3 2018.

Baker Bros. Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2018 after selling out during the quarter.
Baker Bros. Advisors sold 3,753 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2018, an estimated $3.27M.
Baker Bros. Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 12 quarters.
Baker Bros. Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $7.68M in Q3 2017.
45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.